Shots:

• The company will not expand the P-II EMERGE study that assesses Vopratelimab + ipilimumab in PD-(L)1 inhibitor experienced NSCLC patient. Early evaluation of the study showed that the trial will not meet pre-specified interim criteria for continuation of enrollment
• The company also reported the first patient dosing in P-II SELECT study assessing Vopratelimab + JTX-4014 vs JTX-4014 alone in 75 immunotherapy naïve NSCLC patients who have been pre-selected with the TISvopra predictive biomarker with its expected preliminary efficacy data in 2021
• Vopratelimab is a mAb that binds to and activates ICOS which is a protein on the surface of certain T cells found in many solid tumors

  Ref: Jounce Therapeutics | Image: Cowen